Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors

References

• Prati F , Arbustini E , Labellarte A , et al. Eccentric atherosclerotic plaques with positive remodelling have a pericardial distribution: a permissive role of epicardial fat? A three-dimensional intravascular ultrasound study of left anterior descending artery lesions. Eur Heart J . 2003;24(4):329–336.12581680
   PubMed Web of Science ®Google Scholar
• Pezeshkian M , Nouri M , Najjarpour-Jabbari H , et al. Fatty acid composition of epicardial and subcutaneous human adipose tissue. Metab Syndr Relat Disord . 2009;7(2):125–132. doi:10.1089/met.2008.0056 19422139
   PubMed Web of Science ®Google Scholar
• Sacks HS , Fain JN , Holman B , et al. Uncoupling protein-1 and related messenger ribonucleic acids in human epicardial and other adipose tissues: epicardial fat functioning as brown fat. Mol Endocrinol . 2009;23(9):1519–1520. doi:10.1210/mend.23.9.9997
   Google Scholar
• Iacobellis G , Corradi D , Sharma AM . Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med . 2005;2(10):536–543. doi:10.1038/ncpcardio0319 16186852
   PubMedGoogle Scholar
• Baker AR , Silva NF , Quinn DW , et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol . 2006;5:1. doi:10.1186/1475-2840-5-1 16412224
   PubMed Web of Science ®Google Scholar
• Mazurek T , Zhang L , Zalewski A , et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation . 2003;108(20):2460–2466. doi:10.1161/01.CIR.0000099542.57313.C5 14581396
   PubMed Web of Science ®Google Scholar
• Kremen J , Dolinkova M , Krajickova J , et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab . 2006;91(11):4620–4627. doi:10.1210/jc.2006-1044 16895955
   PubMed Web of Science ®Google Scholar
• Chaldakov GN , Fiore M , Stankulov IS , et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res . 2004;146:279–289.14699970
   PubMed Web of Science ®Google Scholar
• Gruzdeva O , Uchasova E , Dyleva Y , et al. Relationships between epicardial adipose tissue thickness and adipo-fibrokine indicator profiles post-myocardial infarction. Cardiovasc Diabetol . 2018;17(1):40. doi:10.1186/s12933-018-0679-y 29548286
   PubMed Web of Science ®Google Scholar
• Xu L , Xu Y , Coulden R , et al. Comparison of epicardial adipose tissue radiodensity threshold between contrast and non-contrast enhanced computed tomography scans: a cohort study of derivation and validation. Atherosclerosis . 2018;275:74–79. doi:10.1016/j.atherosclerosis.2018.05.013 29864608
   PubMed Web of Science ®Google Scholar
• Rosito GA , Massaro JM , Hoffmann U , et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham heart study. Circulation . 2008;117(5):605–613. doi:10.1161/CIRCULATIONAHA.107.743062 18212276
   PubMed Web of Science ®Google Scholar
• Mookadam F , Goel R , Alharthi MS , Jiamsripong P , Cha S . Epicardial fat and its association with cardiovascular risk: a cross-sectional observational study. Heart Views . 2010;11(3):103–108. doi:10.4103/1995-705X.76801 21577377
   PubMedGoogle Scholar
• Matsushita K , Blecker S , Pazin-Filho A , et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes . 2010;59(8):2020–2026. doi:10.2337/db10-0165 20484138
   PubMed Web of Science ®Google Scholar
• Seferovic PM , Petrie MC , Filippatos GS , et al. Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European Society of Cardiology. Eur J Heart Fail . 2018;20(5):853–872. doi:10.1002/ejhf.2018.20.issue-5 29520964
   PubMed Web of Science ®Google Scholar
• Zelniker TA , Wiviott SD , Raz I , et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet . 2019;393(10166):31–39. doi:10.1016/S0140-6736(18)32590-X 30424892
   PubMed Web of Science ®Google Scholar
• Faden G , Faganello G , De Feo S , et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract . 2013;101(3):309–316. doi:10.1016/j.diabres.2013.07.004 23886659
   PubMed Web of Science ®Google Scholar
• Celentano A , Vaccaro O , Tammaro P , et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol . 1995;76(16):1173–1176. doi:10.1016/S0002-9149(99)80330-0 7484905
   PubMed Web of Science ®Google Scholar
• Ferrara D , Montecucco F , Dallegri F , Carbone F . Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol . 2019. doi:10.1002/jcp.28821
   Web of Science ®Google Scholar
• Gao Y , Wang Y-C , Lu C-Q , Zeng C , Chang D , Ju S . Correlations between the abdominal fat-related parameters and severity of coronary artery disease assessed by computed tomography. Quant Imaging Med Surg . 2018;8(6):579–587. doi:10.21037/qims 30140620
   PubMed Web of Science ®Google Scholar
• Yagi S , Hirata Y , Ise T , et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr . 2017;9:78. doi:10.1186/s13098-017-0275-4 29034006
   PubMed Web of Science ®Google Scholar
• Bouchi R , Terashima M , Sasahara Y , et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol . 2017;16(1):32. doi:10.1186/s12933-017-0516-8 28253918
   PubMed Web of Science ®Google Scholar
• Fukuda T , Bouchi R , Terashima M , et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther . 2017;8(4):851–861. doi:10.1007/s13300-017-0279-y 28616806
   PubMed Web of Science ®Google Scholar
• Marchington JM , Pond CM . Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. Int J Obes . 1990;14(12):1013–1022.2086494
   PubMed Web of Science ®Google Scholar
• Sato T , Aizawa Y , Yuasa S , et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol . 2018;17(1):6. doi:10.1186/s12933-017-0658-8 29301516
   PubMed Web of Science ®Google Scholar
• Suresh G , Alva R , Prakash P , Saya R . Prevalence of asymptomatic left ventricular diastolic dysfunction in type 2 diabetic patients and healthy controls: a comparative study. Arch Med Health Sci . 2017;5(1):30.
   Google Scholar
• Francis GS . Diabetic cardiomyopathy: fact or fiction? Heart . 2001;85(3):247–248. doi:10.1136/heart.85.3.247 11179253
   PubMed Web of Science ®Google Scholar
• Pham SV , Chilton RJ . EMPA-REG OUTCOME: the cardiologist’s point of view. Am J Cardiol . 2017;120(1s):S53–s58. doi:10.1016/j.amjcard.2017.05.011 28606345
   PubMed Web of Science ®Google Scholar
• Rajasekeran H , Lytvyn Y , Cherney DZ . Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int . 2016;89(3):524–526. doi:10.1016/j.kint.2015.12.038 26880444
   PubMed Web of Science ®Google Scholar
• Matsutani D , Sakamoto M , Kayama Y , Takeda N , Horiuchi R , Utsunomiya K . Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol . 2018;17(1):73. doi:10.1186/s12933-018-0717-9 29788955
   PubMed Web of Science ®Google Scholar